Dual PPARα/γ activation inhibits SIRT1-PGC1α axis and causes cardiac dysfunction

Dual PPARα/γ agonists that were developed to target hyperlipidemia and hyperglycemia in patients with type 2 diabetes caused cardiac dysfunction or other adverse effects. We studied the mechanisms that underlie the cardiotoxic effects of a dual PPARα/γ agonist, tesaglitazar, in wild-type and diabeti...

Full description

Saved in:
Bibliographic Details
Published in:JCI Insight
Main Authors: Kalliora, Charikleia, Kyriazis, Ioannis D., Oka, Shin-ichi, Lieu, Melissa J., Yue, Yujia, Area-Gomez, Estela, Pol, Christine J., Tian, Ying, Mizushima, Wataru, Chin, Adave, Scerbo, Diego, Schulze, P. Christian, Civelek, Mete, Sadoshima, Junichi, Madesh, Muniswamy, Goldberg, Ira J., Drosatos, Konstantinos
Format: Artigo
Language:Inglês
Published: American Society for Clinical Investigation 2019
Subjects:
Research Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6777908/
https://ncbi.nlm.nih.gov/pubmed/31393858
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.129556
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items